Clinical Trial Update: Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma

View source ↗

Summary

This clinical trial update describes evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker in patients with advanced lung adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Snippet

Sponsor: The University of Hong Kong | Conditions: Adenocarcinoma of Lung (Disorder) | Status: UNKNOWN